OPPPP (1-(3-Oxo-3-phenylpropyl)-4-phenyl-4-piperidinyl propionate) is one of several compounds derived from MPPP, the reversed ester of the opioid analgesic pethidine, which were sold as designer drugs in the 1980s, but have been rarely encountered by law enforcement since the passage of the Federal Analogue Act in 1986.[1] In animal studies it was found to be around 1000× the potency of pethidine,[2] making it several times the potency of fentanyl and with similar hazards of respiratory depression and overdose. It is closely related to numerous compounds made by Janssen et al. for which the structure-activity relationship is well established.[3]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H27NO3 |
Molar mass | 365.473 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Valter K, Arrizabalaga P (1998). Designer Drugs Directory. Elsevier. pp. 147–148, 156. ISBN 0-444-20525-X.
- ^ Carabateas PM, Grumbach L (September 1962). "Strong analgesics. Some 1-substituted 4-phenyl-4-propionoxypiperidines". Journal of Medicinal and Pharmaceutical Chemistry. 91 (5): 913–9. doi:10.1021/jm01240a003. PMID 14056434.
- ^ Janssen PA, Eddy NB (February 1960). "Compounds related to pethidine-IV. New general chemical methods of increasing the analgesic activity of pethidine". Journal of Medicinal and Pharmaceutical Chemistry. 2: 31–45. doi:10.1021/jm50008a003. PMID 14406754.